MD Anderson study suggests psilocybin may prevent chemo-induced neuropathy “Because it works in one neural system, you begin to wonder: Well, what about another?”

FDA shelves Commissioner’s National Priority Voucher program

The FDA’s Commissioner’s National Priority Voucher program is being phased out after months of dormancy, according to reporting from Reuters.

November 13, 2026

By Claire Marie Porter

In Brief

MD Anderson to expand cancer care facilities

The University of Texas MD Anderson Cancer Center announced the expansion of its Texas Medical Center campus through two new facilities: Inspiration Tower and Prism. Together, these facilities will enable UT MD Anderson to care for nearly 250,000 patients annually.

November 13, 2026

In Brief

MD Anderson receives $10M to establish pancreatic cancer interception and prevention program

The University of Texas MD Anderson Cancer Center announced a $10 million commitment from longtime supporters Zelma and William Reid to establish the Pancreatic Cancer High-Risk Interception Program, which will focus on identifying innovative strategies for detecting and intervening against pancreatic cancer in individuals who are at elevated risk for the disease.

November 13, 2026

Drugs & Targets

FDA approves Rybrevant Faspro as dual-targeted therapy for advanced head and neck cancer

FDA granted accelerated approval for Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) (subcutaneous injection, 160 mg/2,000 units per mL) as a single agent for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease has progressed on or after platinum‑based chemotherapy and an anti‑PD‑(L)1 antibody.

November 06, 2026

Vol.52 No.41

Drugs & Targets

FDA grants priority review to Brukinsa combination for first-line mantle cell lymphoma

FDA accepted and granted Priority Review to the supplemental New Drug Application for Brukinsa (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma.

November 06, 2026

Vol.52 No.41

Podcast

Cercek: “The majority of patients in AZUR-1 in a global study were able to avoid all of standard of care”

On Oct. 19, FDA granted an accelerated approval to dostarlimab-gxly (Jemperli) for the treatment of patients with previously untreated stage 2 or stage 3 rectal cancer that is mismatch repair deficient or microsatellite instability–high, as determined by an FDA-authorized test.

November 04, 2026

MD Anderson study suggests psilocybin may prevent chemo-induced neuropathy

“Because it works in one neural system, you begin to wonder: Well, what about another?”

YOU MAY BE INTERESTED IN

FDA shelves Commissioner’s National Priority Voucher program

MD Anderson to expand cancer care facilities

MD Anderson receives $10M to establish pancreatic cancer interception and prevention program

FDA approves Rybrevant Faspro as dual-targeted therapy for advanced head and neck cancer

FDA grants priority review to Brukinsa combination for first-line mantle cell lymphoma

Cercek: “The majority of patients in AZUR-1 in a global study were able to avoid all of standard of care”

Renew today!

Subscriber content

Never miss an issue!

Login